SAN DIEGO — Although fading from use in vasculitis management strategies, cyclophosphamide still offers several benefits for a minority of patients who are unable to switch to other therapies ...

Adding low-dose cyclosphosphamide to rituximab is safe and prolongs relapse-free survival in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, recent study findings ...

Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids ...

Reference Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 Update.

Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "Anti-Neutrophil Cytoplasmic Antibody - Associated Vasculitis - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ...

In the ERG's view, the evidence suggested that rituximab was superior to oral cyclophosphamide (p=0.01) in inducing remission in the subgroup of patients with relapsed severe ANCA-associated ...

In the RITUXVAS trial, 10 patients with ANCA-associated vasculitis and renal involvement were randomly assigned to either 6–10 infusions of cyclophosphamide followed by maintenance therapy with ...

Treatment with avacopan can reduce glucocorticoid use, improve disease control, and recover renal function among patients with ANCA-associated vasculitis, according to a speaker at ACR Convergence ...

The Food and Drug Administration has approved Tavneos™ (avacopan) as an adjunctive treatment for adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis ...